Biofrontera (BFRI) said Wednesday that the last patient completed the one-year follow-up visit in a phase 3 study of the use of Ameluz and RhodoLED photodynamic therapy to treat superficial basal cell carcinoma, a type of skin cancer.
The study evaluated safety and efficacy in 187 patients with at least one clinically and histologically confirmed superficial basal cell carcinomas.
The company said data from the follow-up will be included in its supplemental new drug application submission to the US Food and Drug Administration, expected in Q3.
Biofrontera shares were up nearly 12% in recent trading.
Price: 1.24, Change: +0.13, Percent Change: +11.71
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。